Old North State Wealth Management LLC Acquires 156 Shares of Thermo Fisher Scientific Inc. $TMO

Old North State Wealth Management LLC raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 24.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 804 shares of the medical research company’s stock after purchasing an additional 156 shares during the quarter. Old North State Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $327,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in TMO. CBIZ Investment Advisory Services LLC raised its stake in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 33 shares during the period. Ameriflex Group Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter worth about $30,000. Anderson Financial Strategies LLC purchased a new position in Thermo Fisher Scientific in the 1st quarter worth about $30,000. Keystone Global Partners LLC purchased a new position in Thermo Fisher Scientific in the 1st quarter worth about $31,000. Finally, IMA Advisory Services Inc. purchased a new position in Thermo Fisher Scientific during the 1st quarter valued at about $35,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Raymond James Financial restated an “outperform” rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Barclays upgraded shares of Thermo Fisher Scientific from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $490.00 to $550.00 in a report on Thursday, September 11th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday, September 7th. HSBC restated a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $588.35.

Thermo Fisher Scientific Trading Down 1.9%

NYSE TMO opened at $459.34 on Friday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The firm has a market cap of $173.45 billion, a PE ratio of 26.57, a price-to-earnings-growth ratio of 2.54 and a beta of 0.75. The company has a 50 day moving average price of $475.73 and a 200 day moving average price of $448.37. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific’s revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 9.95%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 400 shares of the company’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.